FindTrial
Sign In

Growth hormone co-treatment on controlled ovarian stimulation in normal ovarian response women can improve embryo quality

Growth hormone co-treatment on controlled ovarian stimulation in normal ovarian response women can improve embryo quality

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900020893
Enrollment
Unknown
Registered
2019-01-21
Start date
2019-01-28
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IVF-ET

Interventions

Case series:growth hormone co-treatment

Sponsors

Northwest Women's and Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) normal ovarian response (age between 20 and 40 years old and previous number of retrieved oocyte between 3 and 15); (2) women with all the embryos graded as poor quality according to Peters cleavage grade embryo scoring system[4] in the previous IVF/ICSI cycle; (3) women with repetitive fresh or frozen embryo transfers without pregnancy.

Exclusion criteria

Exclusion criteria: (1) poor or high ovarian response; (2) women with adjuvant therapy such as DHEA, CoQ10; (3) women with serious and unstable disease, such as cardiovascular disease, cerebrovascular disease; (4) women with recurrent spontaneous abortion; (5) male partner with severe oligoasthenozoospermia or teratozoospermia.

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate;—

Secondary

MeasureTime frame
number of oocytes retrieved;—

Countries

China

Contacts

Public ContactXitong Liu

Northwest Women's and Children's Hospital

liuxitong1989@qq.com+86 13484620246

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026